New biomarker analyses from the stage 3 KEYNOTE-522 trial supply insights into the biological aspects that might affect action to pembrolizumab plus chemotherapy in early-stage triple-negative breast cancer (TNBC).
The brand-new research study, provided by Joyce O'Shaughnessy, MD, at San Antonio Breast Cancer Symposium (SABCS) 2024, likewise enhances the broad advantage of this immunotherapy-chemotherapy mix throughout client subgroups.
The authors analyzed several prospective biomarkers consisting of growth mutational problem (TMB), T-cell– swollen gene expression profile (GEP), and numerous non-T-cell– swollen agreement signatures in relation to pathological total reaction (pCR) and event-free survival (EFS).
The KEYNOTE-522 trial formerly showed that the addition of pembrolizumab to neoadjuvant chemotherapy, followed by adjuvant pembrolizumab, substantially enhanced pCR, EFS, and total survival compared to chemotherapy alone in clients with high-risk, early-stage TNBC.
“This prespecified exploratory analysis examined associations in between prospective biomarkers for pathological reaction and EFS with pembrolizumab, according to a prespecified analytical analysis strategy,” O'Shaughnessy described.
T-Cell Inflammation and TMB are Associated With pCR and EFS
The analysis consisted of 946 clients with entire exome sequencing information and 904 clients with ribonucleic acid sequencing information from pretreatment tissue samples. The scientists discovered that T-cell– swollen GEP was favorably connected with both pCR and EFS, no matter treatment group (P
